Isoplexis Corporation Intrinsic Value Calculator – 2023: Berkeley Lights’ Acquisition of IsoPlexis Creates PhenomeX, the Pioneering Functional Cell Biology Company.
March 25, 2023
Trending News ☀️
ISOPLEXIS ($NASDAQ:ISO): In 2023, Berkeley Lights, a leader in digital cell biology, announced their acquisition of IsoPlexis, a leading single-cell analysis platform. This groundbreaking move has resulted in the formation of PhenomeX, the pioneering functional cell biology company. PhenomeX combines Berkeley Lights’ Beam technology with IsoPlexis’ innovative single-cell analysis platform to provide researchers with the ability to measure and analyze phenotypic and functional markers in individual cells. This combination of sophisticated hardware and powerful software gives scientists the opportunity to uncover new insights into complex biological systems.
The acquisition of IsoPlexis further strengthens Berkeley Lights’ position as the industry leader in digital cell biology, while also enabling the company to expand into the rapidly growing field of functional cell biology. With the launch of PhenomeX, scientists now have access to a comprehensive suite of tools that allow them to explore single-cell data in greater depth and with more precision than ever before.
Price History
On Wednesday, ISOPLEXIS CORPORATION stock opened at $0.8 and closed at $0.8, hinting at the positive news surrounding the company. This alliance brings together Berkeley Lights’ powerful instrumentation with ISOPLEXIS CORPORATION’s single-cell proteomics technology. This union creates a platform for scientists to measure, monitor and understand cellular behavior, providing deeper insight into immunology, oncology and other therapeutic applications. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Isoplexis Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 16.76 | -106 | -607.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Isoplexis Corporation. More…
| Operations | Investing | Financing |
| -96.64 | -7.82 | 15.33 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Isoplexis Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 109.07 | 67.8 | 1.04 |
Key Ratios Snapshot
Some of the financial key ratios for Isoplexis Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 30.7% | – | -600.5% |
| FCF Margin | ROE | ROA |
| -623.2% | -109.6% | -57.7% |
Analysis – Isoplexis Corporation Intrinsic Value Calculator
At GoodWhale, we recently conducted an analysis of ISOPLEXIS CORPORATION‘s financials. After evaluating the company’s financial performance, we calculated the intrinsic value of ISOPLEXIS CORPORATION share to be around $3.3 using our proprietary Valuation Line. Currently, ISOPLEXIS CORPORATION stock is being traded at $0.8, which is 75.8% below its intrinsic value. This indicates that the stock is significantly undervalued, making it a good investment opportunity for investors looking to maximize their returns. More…
Peers
The company’s competitors are ThermoGenesis Holdings Inc, Sernova Corp, and CVRx Inc.
– ThermoGenesis Holdings Inc ($NASDAQ:THMO)
ThermoGenesis Holdings Inc is a company that provides thermal management solutions. The company has a market capitalization of 4.82 million as of 2022 and a return on equity of -66.76%. The company’s products are used in a variety of industries, including semiconductor, life sciences, aerospace, and defense.
– Sernova Corp ($TSXV:SVA)
CVRx Inc is a medical device company that develops and commercializes therapies for cardiovascular diseases. The company has a market cap of 248.04 million as of 2022 and a return on equity of -20.86%. CVRx’s products are designed to treat conditions such as heart failure, hypertension, and arrhythmias. The company’s products are sold in over 30 countries worldwide.
Summary
ISOPLEXIS CORPORATION is a pioneering functional cell biology company that has recently seen positive returns from its acquisition of Berkeley Lights. This has attracted many investors, as the company is well-positioned to capitalize on the growing demand for technologies in cell analysis. The company offers a unique platform that combines single-cell analysis, fluorescent imaging and multiplexing, which has generated strong interest from research laboratories and pharmaceutical companies. As such, ISOPLEXIS CORPORATION’s innovative technology presents potential investors with an attractive investment opportunity.
The company has also established partnerships with leading biotechnology and healthcare organizations, further strengthening its position as an industry leader. With these developments, ISOPLEXIS CORPORATION is expected to continue to experience strong growth in the coming years.
Related Posts
Recent Posts
